Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Bridgebio Oncology Therapeut, ABVX, EYPT, RAPP, BBIO, and represent 45.45% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 6 stocks: Bridgebio Oncology Therapeut (+$207M), ORKA (+$10M), MBX (+$9.2M), RAPP (+$7.5M), AMLX (+$6.8M), RNA.
- Started 3 new stock positions in ORKA, Bridgebio Oncology Therapeut, AMLX.
- Reduced shares in these 10 stocks: MRUS (-$59M), MLTX (-$47M), PRAX (-$33M), VRNA (-$33M), HLXB (-$31M), SPRY (-$19M), JANX (-$16M), INSM (-$16M), ABVX (-$15M), CRGX (-$14M).
- Sold out of its positions in AARD, CRGX, KALA, SPRY, STOK, VRNA, VYNE, HLXB, MRUS.
- Cormorant Asset Management was a net seller of stock by $-85M.
- Cormorant Asset Management has $1.4B in assets under management (AUM), dropping by 7.95%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 36 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bridgebio Oncology Therapeut Com New | 14.3 | $207M | NEW | 18M | 11.58 |
|
| Abivax Sa Sponsored Ads (ABVX) | 11.4 | $166M | -8% | 2.0M | 84.90 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 8.2 | $119M | 8.3M | 14.24 |
|
|
| Rapport Therapeutics (RAPP) | 6.5 | $95M | +8% | 3.2M | 29.70 |
|
| Bridgebio Pharma (BBIO) | 5.0 | $73M | -12% | 1.4M | 51.94 |
|
| Edgewise Therapeutics (EWTX) | 4.5 | $65M | -5% | 4.0M | 16.22 |
|
| Bright Minds Biosciences Com New (DRUG) | 4.4 | $64M | 1.1M | 60.66 |
|
|
| Arcellx Common Stock (ACLX) | 4.4 | $64M | -3% | 775k | 82.10 |
|
| Insmed Com Par $.01 (INSM) | 4.3 | $62M | -20% | 430k | 144.01 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 4.3 | $62M | 2.2M | 28.44 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 3.7 | $53M | -38% | 1.0M | 53.00 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.2 | $47M | -7% | 1.9M | 24.25 |
|
| Pharvaris N V (PHVS) | 2.3 | $34M | -6% | 1.4M | 24.95 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.1 | $30M | 2.4M | 12.65 |
|
|
| Gh Research Ordinary Shares (GHRS) | 1.9 | $27M | -4% | 1.9M | 14.30 |
|
| Cg Oncology (CGON) | 1.7 | $25M | 625k | 40.28 |
|
|
| Korro Bio (KRRO) | 1.5 | $22M | 465k | 47.89 |
|
|
| Mbx Biosciences (MBX) | 1.5 | $21M | +75% | 1.2M | 17.50 |
|
| Mestera (MTSR) | 1.4 | $21M | 400k | 52.33 |
|
|
| Janux Therapeutics (JANX) | 1.4 | $21M | -43% | 850k | 24.44 |
|
| Tarsus Pharmaceuticals (TARS) | 1.2 | $18M | 300k | 59.43 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 1.1 | $17M | 400k | 41.65 |
|
|
| Engene Holdings (ENGN) | 1.1 | $16M | 2.3M | 6.83 |
|
|
| Arcutis Biotherapeutics (ARQT) | 1.0 | $15M | -22% | 775k | 18.85 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.0 | $14M | -76% | 2.0M | 7.17 |
|
| Avidity Biosciences Ord (RNA) | 0.9 | $13M | +50% | 300k | 43.57 |
|
| Bioage Labs (BIOA) | 0.9 | $13M | 2.1M | 5.88 |
|
|
| Axsome Therapeutics (AXSM) | 0.8 | $12M | 100k | 121.45 |
|
|
| Cabaletta Bio (CABA) | 0.8 | $12M | 5.0M | 2.34 |
|
|
| Oruka Therapeutics (ORKA) | 0.7 | $10M | NEW | 533k | 19.23 |
|
| Alumis (ALMS) | 0.6 | $8.6M | 2.1M | 3.99 |
|
|
| Biomea Fusion (BMEA) | 0.5 | $7.2M | 3.6M | 2.02 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.5 | $6.8M | NEW | 500k | 13.59 |
|
| Vaxcyte (PCVX) | 0.4 | $6.3M | 175k | 36.02 |
|
|
| Enliven Therapeutics (ELVN) | 0.3 | $4.1M | 200k | 20.47 |
|
|
| Biohaven (BHVN) | 0.0 | $150k | 10k | 15.01 |
|
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2025 Q3 filed Nov. 14, 2025
- Cormorant Asset Management 2025 Q2 filed Aug. 14, 2025
- Cormorant Asset Management 2025 Q1 filed May 15, 2025
- Cormorant Asset Management 2024 Q4 filed Feb. 14, 2025
- Cormorant Asset Management 2024 Q3 filed Nov. 14, 2024
- Cormorant Asset Management 2024 Q2 filed Aug. 14, 2024
- Cormorant Asset Management 2024 Q1 filed May 15, 2024
- Cormorant Asset Management 2023 Q4 filed Feb. 14, 2024
- Cormorant Asset Management 2023 Q3 filed Nov. 14, 2023
- Cormorant Asset Management 2023 Q2 filed Aug. 14, 2023
- Cormorant Asset Management 2023 Q1 filed May 15, 2023
- Cormorant Asset Management 2022 Q4 filed Feb. 14, 2023
- Cormorant Asset Management 2022 Q3 filed Nov. 14, 2022
- Cormorant Asset Management 2022 Q2 filed Aug. 15, 2022
- Cormorant Asset Management 2022 Q1 filed May 16, 2022
- Cormorant Asset Management 2021 Q4 filed Feb. 14, 2022